Skip Navigation LinksHome > Academic & Industry > Proposal Submission  

ANNOUNCEMENT: ADCS Request for Preliminary Proposals

The Alzheimer's Disease Cooperative Study (ADCS) requests preliminary proposals for therapeutic trials to be conducted by the ADCS with potential funding from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH).

The ADCS is a consortium of academic medical centers established by the NIA in 1991 to contribute to AD therapeutic research. The group conducts Phase II and III trials that might not be conducted without NIH support. Trials completed by the ADCS have investigated selegiline and vitamin E (Sano et al, NEJM 336:1216, 1997), prednisone (Aisen et al, Neurology, 54: 588, 2000), estrogen (Mulnard et al, JAMA, 283: 1007, 2000), haloperidol, trazodone and behavior management (Teri et al, Neurology 55: 1271, 2000), non-steroidal anti-inflammatory drugs (Aisen et al, JAMA, 289: 2819, 2003), melatonin (Singer et al, Sleep, 26: 893, 2003), valproic acid (Tariot et al, Am J Geriatr Psychiatry, 13: 942, 2005), donepezil and vitamin E in mild cognitive impairment (Petersen et al, NEJM, 352: 2379, 2005), B vitamins (Aisen et al, JAMA, 300:1774, 2007) and simvastatin (Sano et al, in preparation), among others. ADCS studies currently in progress include trials of valproate for behavioral prophylaxis, DHA, pooled human immunoglobulin (IgIV), an inhibitor of the Receptor for Advanced Glycation Endproducts (RAGE) and NGF gene delivery. The ADCS also conducts instrument development studies. The ADCS has extensive expertise in implementing imaging and biofluid biomarkers as adjuncts to clinical trials.

Proposals may be submitted by academic investigators and/or companies interested in the development of new therapies for AD.

Preliminary proposals should be one to four pages in length, and include*:

   1. Proposed compound
   2. Rationale for therapeutic development for AD, including mechanism of action
   3. in vitro and in vivo studies supporting development for AD (if done)
   4. preclinical toxicology (if done)
   5. Evidence of brain penetration
   6. Any human studies of the compound

*All information provided by applicants will be considered confidential and will not be disclosed outside the ADCS.

Preliminary proposals will be reviewed by a subcommittee of the ADCS Steering Committee. For those projects that are potentially appropriate for the ADCS, proposals will be developed further jointly by the applicant and the ADCS.

Requests for additional information on and preliminary proposals may be submitted at any time by email to:

Howard Feldman, MDCM, FRCP (C)
Director of the Alzheimer’s Disease Cooperative Study
Dean, Alzheimer’s Disease and Neurodegenerative Research

Additional information on the ADCS can be found at the organization's website: